Core Insights - The company reported a steady growth in its main business, with a revenue of 713.42 million yuan, representing an 11.02% year-on-year increase, driven primarily by the strong performance of its core medical device business [2] - Despite a decline in net profit attributable to shareholders by 31.09% to 51.93 million yuan due to exchange rate fluctuations and stock incentive costs, the adjusted net profit increased by 20.99% when excluding these factors, indicating healthy profitability in core operations [2] - The company is actively expanding its global market presence, with its FibroScan series devices installed in over 100 countries and regions, reflecting a successful transition from single device sales to a comprehensive "device + service" solution [3] Revenue Growth Drivers - The FibroScan series devices generated sales revenue of 482 million yuan, marking a 13.8% increase, while the pharmaceutical business remained stable with self-owned drug revenue reaching 14.9 million yuan, and e-commerce channel revenue surged by 59.23% [2] - The gross profit margin stood at 75.26%, and the debt-to-asset ratio decreased by 1.22 percentage points to 28.99%, indicating a strengthening financial structure [2] Global Business Resilience - The company’s subsidiary Echosens achieved a net profit of 74.39 million yuan, up 1.76%, further solidifying its leading position in the non-invasive diagnosis of liver diseases [3] - Collaborations with international pharmaceutical companies, such as Boehringer Ingelheim and Novo Nordisk, are being pursued to enhance the diagnostic ecosystem for metabolic fatty liver disease [3] R&D Innovation and Market Expansion - The company is advancing its integrated strategy for liver disease diagnosis and treatment, with the new generation of FibroScan devices being promoted globally [4] - Domestic market expansion includes building a secondary prevention system for liver cancer and developing pediatric liver disease networks through partnerships with renowned hospitals [4] - The implementation of an employee stock ownership plan and stock buyback initiatives reflects the company's commitment to aligning employee interests with long-term goals [4]

Group 1: Company Performance and Goals - The company is confident in achieving its annual target of installing 4,000 units by the end of 2025 [1] - In the first half of 2025, the company plans to install 2,400 units, which is an increase of nearly 5 times compared to the previous year [5] - As of July 10, 2025, the number of shareholders is 20,833 [5] Group 2: Product and Market Insights - FibroScan devices are recognized by multiple authoritative organizations, including WHO and EASL, as a standard for liver disease detection [3] - The global market size for varicose vein ultrasound treatment devices is estimated to be approximately $1.06 billion in 2024 [6] - The company’s device, FibroScan, has a cost of about €10,000 per unit, requiring 250 tests to break even [1] Group 3: Financial and Operational Strategies - The company has conducted special studies to mitigate the impact of currency fluctuations on financial reports [2] - Revenue from the device business, including per-use charges and leasing, amounted to 412 million yuan, accounting for 44.62% of total revenue [7] - The company has transitioned all dollar-denominated funds into euros to minimize exchange rate impacts [6] Group 4: Collaborations and Partnerships - The company collaborates with domestic MASH drug research enterprises for the FibroScan series devices [1] - Echosens, a partner in Europe, operates under a mixed model of direct sales and distribution in certain countries [2] - The company is actively pursuing strategic partnerships to enhance its market presence and product offerings [4]